Marker Therapeutics (FRA:GX1) Total Liabilities : €2.82 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Marker Therapeutics Total Liabilities?

Marker Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was €2.82 Mil.

Marker Therapeutics's quarterly Total Liabilities declined from Jun. 2023 (€2.70 Mil) to Sep. 2023 (€2.60 Mil) but then increased from Sep. 2023 (€2.60 Mil) to Dec. 2023 (€2.82 Mil).

Marker Therapeutics's annual Total Liabilities declined from Dec. 2021 (€21.37 Mil) to Dec. 2022 (€13.99 Mil) and declined from Dec. 2022 (€13.99 Mil) to Dec. 2023 (€2.82 Mil).

Marker Therapeutics Total Liabilities Historical Data

The historical data trend for Marker Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marker Therapeutics Total Liabilities Chart

Marker Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

2.05

15.02

21.37

13.99

2.82

Marker Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															13.99	11.23	2.70	2.60	2.82

Marker Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Marker Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.82	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.82

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	15.705	-	12.887
	=	2.82

Marker Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.82	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.82

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	15.705	-	12.887
	=	2.82

Marker Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Marker Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Marker Therapeutics (FRA:GX1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

MRKR:USA

Address

4551 Kennedy Commerce Drive, Houston, TX, USA, 77032

Website

http://www.markertherapeutics.com

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Marker Therapeutics (FRA:GX1) Headlines

No Headlines